Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors, 54629-54630 [2023-17256]
Download as PDF
Federal Register / Vol. 88, No. 154 / Friday, August 11, 2023 / Notices
Place: Porter Neuroscience Research
Center, Building 35A, Room 620/630, 35
Convent Drive, Bethesda, MD 20892.
Open: September 15, 2023, 10:00 a.m. to
11:50 a.m.
Agenda: Staff reports on divisional,
programmatical, and special activities.
Place: Porter Neuroscience Research
Center, Building 35A, Room 620/630, 35
Convent Drive, Bethesda, MD 20892.
Contact Person: Rebecca Wagenaar-Miller,
Ph.D., Director, Division of Extramural
Activities, NIDCD/NIH, 6001 Executive
Boulevard, Bethesda, MD 20892, (301) 496–
8693, rebecca.wagenaar-miller@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcd.nih.gov/about/advisory-council,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: August 8, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–17252 Filed 8–10–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute of Nursing Research;
Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Nursing Research.
This will be a hybrid meeting held inperson and virtually and will be open to
the public as indicated below.
Individuals who plan to attend inperson or view the virtual meeting and
need special assistance or other
reasonable accommodations, should
VerDate Sep<11>2014
16:59 Aug 10, 2023
Jkt 259001
notify the Contact Person listed below
in advance of the meeting. The meeting
can be accessed from the NIH Videocast
at the following link: https://videocast.
nih.gov/watch=51158.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Nursing Research.
Date: September 12, 2023.
Open: 9:00 a.m. to 10:30 a.m.
Agenda: Call to Order and Opening
Remarks, NINR Director’s Report, NCATS
Updates, Priorities, and Opportunities for
Collaboration.
Place: National Institutes of Health,
Building 31, C-Wing, Sixth Floor, Rooms
A&B, 31 Center Drive, Bethesda, MD 20892
(Hybrid Meeting).
Open: 10:45 a.m. to 12:30 p.m.
Agenda: Community Partnerships to
Advance Science for Society (ComPASS)
Initiative, Artificial Intelligence/Machine
Learning Consortium to Advance Health
Equity and Researcher Diversity (AIM–
AHEAD) Program.
Place: National Institutes of Health,
Building 31, C-Wing, Sixth Floor, Rooms
A&B, 31 Center Drive, Bethesda, MD 20892
(Hybrid Meeting).
Open: 1:00 p.m. to 3:00 p.m.
Agenda: CSR Initiatives Related to
Strengthening Review Panel Diversity,
Addressing Bias, and Evaluating Panel
Quality, Implementing a Maternal health and
Pregnancy Outcomes Vision for Everyone
(IMPROVE) Initiative, Concepts, Council
Open Discussion, Adjournment.
Place: National Institutes of Health,
Building 31, C-Wing, Sixth Floor, Rooms
A&B, 31 Center Drive, Bethesda, MD 20892
(Hybrid Meeting).
Closed: 3:00 p.m. to 3:20 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, C-Wing, Sixth Floor, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Elizabeth Tarlov, Ph.D.,
RN, Director, Division of Extramural Science
Programs (DESP), National Institute of
Nursing Research, Bethesda, MD 20892, (301)
594–1580, elizabeth.tarlov@nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of an organization may
submit a letter of intent, a brief description
of the organization represented and a short
description of the oral presentation. Only one
representative of an organization may be
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
54629
allowed to present oral comments and
presentations may be limited to five minutes.
Both printed and electronic copies are
requested for the record. In addition, any
interested person may file written comments
with the committee by forwarding the
statement to the Contact Person listed on this
notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.ninr.nih.gov/aboutninr/nacnr, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.361, Nursing Research,
National Institutes of Health, HHS)
Dated: August 8, 2023.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–17253 Filed 8–10–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Manufacture,
Distribution, Sale and Use of T-CellBased Immunotherapies for Solid
Tumors
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Eunice Kennedy Shriver
National Institute of Child Health and
Human Development and the National
Cancer Institute, both institutes of the
National Institutes of Health,
Department of Health and Human
Services, are contemplating the grant of
an Exclusive Patent License to practice
the inventions embodied in the Patents
and Patent Applications listed in the
Supplementary Information section of
this Notice to EnZeta Immunotherapies,
Inc. of the State of Delaware.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
SUMMARY:
E:\FR\FM\11AUN1.SGM
11AUN1
54630
Federal Register / Vol. 88, No. 154 / Friday, August 11, 2023 / Notices
on or before August 28, 2023 will be
considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Richard T. Girards, Jr., Esq.,
MBA, Senior Technology Transfer
Manager, National Institutes of Health,
NCI Technology Transfer Center by
email (richard.girards@nih.gov) or
phone (240–276–6825).
SUPPLEMENTARY INFORMATION:
lotter on DSK11XQN23PROD with NOTICES1
Intellectual Property
E–010–2021: Enhanced Antigen
Reactivity of Immune Cells Expressing a
Mutant Non-Signaling CD3 Zeta Chain
1. United States Provisional Patent
Application No. 63/113,428, filed 13
November 2020 (HHS Reference No. E–
010–2021–0–US–01);
2. International Patent Application
No. PCT/US2021/059109, filed 12
November 2021 (HHS Reference No. E–
010–2021–0–PCT–02);
3. United States Patent Application
No. 18/036,112, filed 09 May 2023 (HHS
Reference No. E–010–2021–0–US–02);
4. European Patent Application No.
21824143.8, filed 30 March 2023 (HHS
Reference No. E–010–2021–0–EP–01);
and
5. any and all other U.S. and ex-U.S.
patents and patent applications
claiming priority to any one of the
foregoing, now or in the future.
The patent and patent application
rights in these inventions have been
assigned and/or exclusively licensed to
the Government of the United States of
America.
The prospective exclusive license
territory may be worldwide and the
fields of use may be limited to the
following: manufacture, distribution,
sale and use of T-cell-based
immunotherapies for solid tumors.
These technologies disclose, e.g., cells
expressing a modified CD3 subunit
chain comprising at least one ITAM
deletion. The inventive cells and
populations thereof can be formulated
into a composition, such as a
pharmaceutical composition. Such cells
and compositions thereof can be
utilized to treat a wide variety of
conditions, including but not limited to
the indications within the scope of the
contemplated exclusive license.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR 404. The
prospective exclusive license will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
VerDate Sep<11>2014
16:59 Aug 10, 2023
Jkt 259001
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: August 8, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2023–17256 Filed 8–10–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Interagency Autism
Coordinating Committee.
The meeting will be open to the
public to attend in person or virtually.
In person attendance is limited to space
available. Advanced registration is
recommended. Virtual viewing will be
accessible via NIH Videocast (https://
videocast.nih.gov/). Individuals who
plan to attend in person or virtually and
need special assistance or other
reasonable accommodations should
submit a request to the Contact Person
listed on this notice at least seven (7)
days prior to the meeting.
Name of Committee: Interagency Autism
Coordinating Committee (IACC).
Date: October 11, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To discuss business, updates, and
issues related to autism research and services
activities.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, First Floor Conference Room,
Rockville, MD 20852.
Cost: The meeting is free and open to the
public.
Registration: A registration web link will
be posted on the IACC website
(www.iacc.hhs.gov) prior to the meeting. Preregistration is recommended.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Deadlines: Public Comment Due Date:
Wednesday, September 20, 2023, by 5:00
p.m. ET.
Public Comment Guidelines: For public
comment instructions, see below.
Contact Person: Ms. Rebecca Martin, Office
of National Autism Coordination, National
Institute of Mental Health, NIH, Phone: 301–
435–0886, Email: IACCPublicInquiries@
mail.nih.gov.
Public Comments: The IACC welcomes
written and oral public comments from
members of the autism community and asks
the community to review and adhere to its
Public Comment Guidelines. In the 2021–
2023 IACC Strategic Plan, the IACC lists the
‘‘Spirit of Collaboration’’ as one of its core
values, stating that, ‘‘We will treat others
with respect, listen with open minds to the
diverse lived experiences of people on the
autism spectrum and their families, consider
multiple solutions, and foster discussions
where participants can comfortably share
different opinions.’’ In keeping with this core
value, the IACC and the NIMH Office of
National Autism Coordination (ONAC) ask
that members of the public who provide
public comments or participate in meetings
of the IACC also adhere to this core value.
A limited number of slots are available for
individuals to provide a ∼3-minute summary
or excerpt of their written comment to the
Committee during the meeting. For those
interested in that opportunity, please
indicate ‘‘Interested in providing oral
comment’’ in your written submission, along
with your name, address, email, phone
number, and professional/organizational
affiliation so that ONAC staff can contact you
if a slot is available for you to provide a
summary or excerpt of your comment during
the meeting.
For any given meeting, priority for
comment slots will be given to individuals
and organizations that have not previously
provided comments in the current calendar
year. This will help ensure that as many
individuals and organizations as possible
have an opportunity to share comments.
Commenters going over their allotted 3minute slot may be asked to conclude
immediately in order to allow other
comments and the rest of the meeting to
proceed on schedule.
Public comment submissions received by
5:00 p.m. ET on Wednesday, September 20,
2023, will be provided to the Committee
prior to the meeting for their consideration.
Any written comments received after 5:00
p.m. ET, Wednesday, September 20, 2023,
may be provided to the Committee either
before or after the meeting, depending on the
volume of comments received and the time
required to process them in accordance with
privacy regulations and other applicable
Federal policies. The Committee is not able
to respond individually to comments. All
public comments become part of the public
record. Attachments of copyrighted
publications are not permitted, but web links
or citations for any copyrighted works cited
may be provided. For public comment
guidelines, see: https://iacc.hhs.gov/
meetings/public-comments/guidelines/.
Technical issues: If you experience any
technical problems with the webcast, please
email IACCPublicInquiries@mail.nih.gov.
E:\FR\FM\11AUN1.SGM
11AUN1
Agencies
[Federal Register Volume 88, Number 154 (Friday, August 11, 2023)]
[Notices]
[Pages 54629-54630]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-17256]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Manufacture,
Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid
Tumors
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Eunice Kennedy Shriver National Institute of Child Health
and Human Development and the National Cancer Institute, both
institutes of the National Institutes of Health, Department of Health
and Human Services, are contemplating the grant of an Exclusive Patent
License to practice the inventions embodied in the Patents and Patent
Applications listed in the Supplementary Information section of this
Notice to EnZeta Immunotherapies, Inc. of the State of Delaware.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center
[[Page 54630]]
on or before August 28, 2023 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated Exclusive Patent License
should be directed to: Richard T. Girards, Jr., Esq., MBA, Senior
Technology Transfer Manager, National Institutes of Health, NCI
Technology Transfer Center by email ([email protected]) or phone
(240-276-6825).
SUPPLEMENTARY INFORMATION:
Intellectual Property
E-010-2021: Enhanced Antigen Reactivity of Immune Cells Expressing a
Mutant Non-Signaling CD3 Zeta Chain
1. United States Provisional Patent Application No. 63/113,428,
filed 13 November 2020 (HHS Reference No. E-010-2021-0-US-01);
2. International Patent Application No. PCT/US2021/059109, filed 12
November 2021 (HHS Reference No. E-010-2021-0-PCT-02);
3. United States Patent Application No. 18/036,112, filed 09 May
2023 (HHS Reference No. E-010-2021-0-US-02);
4. European Patent Application No. 21824143.8, filed 30 March 2023
(HHS Reference No. E-010-2021-0-EP-01); and
5. any and all other U.S. and ex-U.S. patents and patent
applications claiming priority to any one of the foregoing, now or in
the future.
The patent and patent application rights in these inventions have
been assigned and/or exclusively licensed to the Government of the
United States of America.
The prospective exclusive license territory may be worldwide and
the fields of use may be limited to the following: manufacture,
distribution, sale and use of T-cell-based immunotherapies for solid
tumors.
These technologies disclose, e.g., cells expressing a modified CD3
subunit chain comprising at least one ITAM deletion. The inventive
cells and populations thereof can be formulated into a composition,
such as a pharmaceutical composition. Such cells and compositions
thereof can be utilized to treat a wide variety of conditions,
including but not limited to the indications within the scope of the
contemplated exclusive license.
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
404. The prospective exclusive license will be royalty bearing, and the
prospective exclusive license may be granted unless within fifteen (15)
days from the date of this published Notice, the National Cancer
Institute receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: August 8, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-17256 Filed 8-10-23; 8:45 am]
BILLING CODE 4140-01-P